Physician profile
Roberto Fogel
NPI 1083033765
$9,181.68
in general payments reported to CMS, 2019-2025
34 companies · $3,641 in 2025
The $3,641 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.93 · 2022: $1,066 · 2023: $1,661 · 2024: $2,794 · 2025: $3,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,012 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,012.03 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,278.21 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,037.05 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $858.12 | 2022-2025 | Tremfya, Stelara, Simponi |
| Phathom Pharmaceuticals, INC. | $720.41 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $615.82 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $506.12 | 2023-2025 | |
| Celgene Corporation | $314.89 | 2022-2024 | Zeposia |
| Genzyme Corporation | $313.40 | 2022-2025 | |
| Gilead Sciences, INC. | $310.26 | 2024-2025 | Livdelzi |
| Ardelyx, INC. | $269.74 | 2024-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $258.41 | 2024-2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $221.09 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $191.76 | 2022-2025 | Ocaliva |
| Vivus LLC | $185.01 | 2022-2025 | Qsymia, Pancreaze |
| Aimmune Therapeutics, INC. | $143.56 | 2024-2025 | Zenpep |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $122.31 | 2024 | |
| Lilly USA, LLC | $118.64 | 2024-2025 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.78 | 2023 | Cyltezo |
| Anx Robotica Corp | $73.08 | 2022 | |
| Ironwood Pharmaceuticals, INC | $69.44 | 2023 | Linzess |
| Apollo Endosurgery US INC | $60.78 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.86 | 2024-2025 | Xifaxan, Trulance |
| Ambu INC. | $54.94 | 2022 | |
| Novo Nordisk INC | $50.39 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $45.43 | 2023 | Rebyota |
| Pentax of America, INC. | $41.47 | 2022 | |
| Organon LLC | $30.49 | 2023-2025 | Hadlima |
| Redhill Biopharma INC. | $27.55 | 2022 | |
| Biocon Biologics INC | $24.52 | 2025 | Yesintek |
| Celltrion USA INC. | $23.38 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $21.28 | 2025 | Sutab, Suflave |
| Amgen INC. | $17.84 | 2022 | |
| Endogastric Solutions, INC | $14.98 | 2023 | Esophyx |
| Olympus America INC. | $14.67 | 2023 | Single Use Grasping Forceps |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Fogel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.